Changing Strategies To Protect Your Autonomous AI's IP
An August article in MIT Technology Review examined an awkward fact about a well-advertised drug discovery driven by artificial intelligence.[1] The biotech company Insilico Medicine had publicly credited its generative AI...To view the full article, register now.
Already a subscriber? Click here to view full article